BWI: Sun Pharma Signs Agreement with MedImmune for Generic Ethyol®

Press release from Business Wire India
Source: Sun Pharmaceuticals Industries Ltd
Monday, August 03, 2009 02:20 PM IST (08:50 AM GMT)
Editors: General: Consumer interest, Economy; Business: Business services, Healthcare, biotechnology & pharmaceutical; Healthcare
————————————————–
Sun Pharma Signs Agreement with MedImmune for Generic Ethyol®

Mumbai, Maharashtra, India, Monday, August 03, 2009 — (Business Wire India) — Sun Pharmaceutical Industries Ltd (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE:SUNPHARMA, BSE: 524715) announced today that it has, along with its subsidiaries (collectively, Sun Pharma), executed a settlement agreement with MedImmune, stipulating the dismissal of the lawsuits filed in the United States District Court for the District of Maryland regarding the submission of an Abbreviated New Drug Application (ANDA) for a generic version of Ethyol®.

Under the settlement agreement, MedImmune interalia grants Sun Pharma a license to certain patents, permitting Sun Pharma to continue marketing the generic version of Ethyol® in the United States. The settlement resolves the entirety of the litigations between the parties.

The terms of the settlement are confidential.

Ethyol® is a registered trademark MedImmune.

About Sun Pharmaceutical Industries Ltd.

Established in 1983, listed since 1994 and headquartered in India, Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE:SUNPHARMA, BSE: 524715) is an international, integrated, speciality pharmaceutical company. It manufactures and markets a large basket of pharmaceutical formulations as branded generics as well as generics in India, US and several other markets across the world. In India, the company is a leader in niche therapy areas of psychiatry, neurology, cardiology, diabetology, gastroenterology, and orthopedics. The company has strong skills in product development, process chemistry, and manufacturing of complex API, as well as dosage forms. More information about the company can be found at www.sunpharma.com.

CONTACT DETAILS
Uday Baldota, Sun Pharmaceuticals Industries Ltd, +91 (22) 66455645, Extn: 605, +91 (22) 66455605, +91 9867010529, [email protected]
Mira Desai, Sun Pharmaceuticals Industries Ltd, +91 (22) 66455645, Extn: 606, +91 (22) 66455606, +91 9821923797, [email protected]

KEYWORDS
CONSUMER, ECONOMY, BUSINESS SERVICES, HEALTHCARE, HEALTHCARE

If you wish to change your Business Wire India selection please click on this link http://www.businesswireindia.com/media/news.asp and use your personal username and password to login.

Submit your press release at http://www.businesswireindia.com

BWI: Sun Pharma Signs Agreement with MedImmune for Generic Ethyol®

Press release from Business Wire India
Source: Sun Pharmaceuticals Industries Ltd
Monday, August 03, 2009 02:20 PM IST (08:50 AM GMT)
Editors: General: Consumer interest, Economy; Business: Business services, Healthcare, biotechnology & pharmaceutical; Healthcare
————————————————–
Sun Pharma Signs Agreement with MedImmune for Generic Ethyol®

Mumbai, Maharashtra, India, Monday, August 03, 2009 — (Business Wire India) — Sun Pharmaceutical Industries Ltd (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE:SUNPHARMA, BSE: 524715) announced today that it has, along with its subsidiaries (collectively, Sun Pharma), executed a settlement agreement with MedImmune, stipulating the dismissal of the lawsuits filed in the United States District Court for the District of Maryland regarding the submission of an Abbreviated New Drug Application (ANDA) for a generic version of Ethyol®.

Under the settlement agreement, MedImmune interalia grants Sun Pharma a license to certain patents, permitting Sun Pharma to continue marketing the generic version of Ethyol® in the United States. The settlement resolves the entirety of the litigations between the parties.

The terms of the settlement are confidential.

Ethyol® is a registered trademark MedImmune.

About Sun Pharmaceutical Industries Ltd.

Established in 1983, listed since 1994 and headquartered in India, Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE:SUNPHARMA, BSE: 524715) is an international, integrated, speciality pharmaceutical company. It manufactures and markets a large basket of pharmaceutical formulations as branded generics as well as generics in India, US and several other markets across the world. In India, the company is a leader in niche therapy areas of psychiatry, neurology, cardiology, diabetology, gastroenterology, and orthopedics. The company has strong skills in product development, process chemistry, and manufacturing of complex API, as well as dosage forms. More information about the company can be found at www.sunpharma.com.

CONTACT DETAILS
Uday Baldota, Sun Pharmaceuticals Industries Ltd, +91 (22) 66455645, Extn: 605, +91 (22) 66455605, +91 9867010529, [email protected]
Mira Desai, Sun Pharmaceuticals Industries Ltd, +91 (22) 66455645, Extn: 606, +91 (22) 66455606, +91 9821923797, [email protected]

KEYWORDS
CONSUMER, ECONOMY, BUSINESS SERVICES, HEALTHCARE, HEALTHCARE

If you wish to change your Business Wire India selection please click on this link http://www.businesswireindia.com/media/news.asp and use your personal username and password to login.

Submit your press release at http://www.businesswireindia.com